Vaccination in B-cell-depleted patients with multiple sclerosis

Affiliations

¹ From the Department of Neurology (J.K.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Department of Clinical Neurosciences (R.D.P.), Service of Neurology, Lausanne University Hospital and University of Lausanne, Switzerland; Department of Neurology (B.H.), School of Medicine, Technical University of Munich; and Munich Cluster for Systems Neurology (B.H.), Munich, Germany. j.killestein@vumc.nl.
² From the Department of Neurology (J.K.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Department of Clinical Neurosciences (R.D.P.), Service of Neurology, Lausanne University Hospital and University of Lausanne, Switzerland; Department of Neurology (B.H.), School of Medicine, Technical University of Munich; and Munich Cluster for Systems Neurology (B.H.), Munich, Germany.

Editorial

Joep Killestein et al. Neurology. 2020.

. 2020 Oct 6;95(14):613-614.

doi: 10.1212/WNL.0000000000010378. Epub 2020 Jul 29.

¹ From the Department of Neurology (J.K.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Department of Clinical Neurosciences (R.D.P.), Service of Neurology, Lausanne University Hospital and University of Lausanne, Switzerland; Department of Neurology (B.H.), School of Medicine, Technical University of Munich; and Munich Cluster for Systems Neurology (B.H.), Munich, Germany. j.killestein@vumc.nl.
² From the Department of Neurology (J.K.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Department of Clinical Neurosciences (R.D.P.), Service of Neurology, Lausanne University Hospital and University of Lausanne, Switzerland; Department of Neurology (B.H.), School of Medicine, Technical University of Munich; and Munich Cluster for Systems Neurology (B.H.), Munich, Germany.

No abstract available

Comment on

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, Manfrini M, McNamara J, Robertson DS, Stokmaier D, Wendt JK, Winthrop KL, Traboulsee A. Bar-Or A, et al. Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29. Neurology. 2020. PMID: 32727835 Free PMC article. Clinical Trial.